MCL Literature Feed

An albumin nanocomplex of the BCL-2/xL inhibitor APG-1252 reduces thrombocytopenia and enhances anti-MCL efficacy in mouse models, offering a potential strategy to improve the therapeutic window.

A patient-derived organoid model from prostate-metastatic MCL predicted sensitivity to gemcitabine but resistance to rituximab/oxaliplatin, offering a new platform for personalized therapy selection in heterogeneous disease.

This review highlights the diagnostic challenge of distinguishing mantle cell lymphoma with plasmacytic differentiation from multiple myeloma, particularly the CCND1-translocated subtype, emphasizing the need for careful molecular workup.

Long-term follow-up (37.2 months) in Japanese relapsed/refractory MCL patients shows the ibrutinib-venetoclax combination yields durable complete responses (83% CR), high MRD negativity, and a manageable safety profile.

This Delphi consensus provides a framework to overcome CAR-T referral barriers in MCL, emphasizing early patient identification and structured collaboration between centers to improve access and timeliness of therapy.

The Japanese PMDA has approved the BTK inhibitor acalabrutinib for treating mantle cell lymphoma, providing a new therapeutic option for patients in Japan.

This review advocates for integrating BTK inhibitors into frontline MCL therapy for all patients, particularly for TP53-mutated disease, challenging the standard role of chemotherapy.

This first-of-its-kind case report documents mantle cell lymphoma presenting as appendiceal intussusception, highlighting a rare gastrointestinal manifestation to consider in elderly patients with this surgical emergency.

This study evaluates the novel, chemotherapy-free combination of PI3Ki copanlisib and BCL2i venetoclax as a new targeted therapy for patients with relapsed/refractory mantle cell lymphoma.

A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.

CT-based radiomics combined with machine learning accurately differentiates MCL from other lymphomas non-invasively, potentially improving diagnostic precision and guiding biopsies in treatment-naïve patients.

This large real-world study confirms brexucabtagene autoleucel's high efficacy (91% ORR, 63% 1-yr PFS) in R/R MCL, supporting its standard-of-care role and suggesting earlier use improves outcomes.

This case report of MCL with atypical cytology (abundant, irregular cytoplasm) highlights the crucial role of flow cytometry in achieving an accurate diagnosis when morphology is misleading.

Frontline ibrutinib-rituximab improves progression-free survival over immunochemotherapy in older MCL patients, establishing a new chemotherapy-free standard of care option.

This review provides a framework for selecting frontline therapies for older MCL patients, weighing less-intensive chemoimmunotherapy against novel agents like BTK inhibitors based on patient-specific factors.

This preclinical study engineers novel nanocarriers for cytarabine, aiming to improve drug delivery and anti-lymphoma efficacy, which could enhance existing high-dose MCL chemotherapy regimens.

Mantle cell lymphoma can present with multiple distinct endoscopic and histologic morphologies in the colorectum, requiring high clinical suspicion for accurate diagnosis during gastrointestinal evaluation.

The novel oral CDK9 inhibitor YX0798 demonstrates high selectivity and potent preclinical activity in MCL by downregulating MYC/MCL-1, offering a potential strategy to overcome therapeutic resistance.

This case report describes a rare presentation of MCL as bilateral upper eyelid entropion, highlighting an unusual ocular manifestation that expands the differential diagnosis for clinicians.

This review details the oncogenic role of the FoxO1 transcription factor in MCL, highlighting its potential as a novel therapeutic target with specific preclinical inhibitors under investigation.

This review details how MCL cell adhesion within the microenvironment promotes survival, explaining the mechanism of action for TME-disrupting therapies and its role in drug resistance.

This case report describes a rare presentation of primary thyroid MCL causing life-threatening airway compromise, emphasizing its inclusion in the differential diagnosis for rapidly enlarging neck masses.

This long-term Italian study confirms poor outcomes for allo-HSCT in relapsed/refractory MCL (27% 3-year PFS), with no survival benefit if not in complete remission pre-transplant.

This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.

This review summarizes advanced 3D culture models that better mimic the MCL microenvironment, offering improved platforms for preclinical drug screening and developing personalized medicine.

This Danish nationwide study confirms blastoid morphology, high Ki67, and high CNS-IPI as key risk factors for secondary CNS lymphoma, supporting consideration of upfront CNS screening in high-risk patients.

This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.

In a US community setting, real-world data shows MCL patients on zanubrutinib had significantly longer treatment duration and adherence compared to acalabrutinib and ibrutinib, suggesting better persistence.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

Adding venetoclax to RBAC chemo-immunotherapy improves 2-year progression-free survival to 60% for older, high-risk MCL patients, validating a new risk-stratified, fixed-duration frontline treatment.